SAN DIEGO, June 27 /PRNewswire/ -- Granite Financial has today issued a BUY recommendation on Boston Biomedica, Inc. (Nasdaq: BBII) -- $4.00. A 12 page research report has been prepared. The analyst is David N. Allen.
Granite Financial regards Boston Biomedica as a special situation with revenue growth potential in infectious disease diagnostics and genomic analysis. We believe there is major upside potential from the Company's two development programs. One is in HIV and viral therapeutics and the other is in Pressure Cycling Technology (PCT). We believe an earnings turnaround is expected in Q4-2000 or Q1-2001. Our price target for the stock is $7.25 within 18 months.
David N. Allen C.F.A.
Granite Financial Group, Inc.
Tel: (858) 509-8800
SOURCE Granite Financial Group, Inc.
CONTACT: David N. Allen C.F.A. of Granite Financial Group, Inc., 858-509-8800